Search

Your search keyword '"Subirá, D."' showing total 135 results
Start Over Author "Subirá, D."
135 results on '"Subirá, D."'

2. Outcomes of an enhanced recovery after radical cystectomy program in a prospective multicenter study: compliance and key components for success

Author

Llorente, C., Guijarro, A., Hernández, V., Fernández-Conejo, G., Passas, J., Aguilar, L., Tejido, A., Hernández, C., Moralejo, M., Subirá, D., González-Enguita, C., Husillos, A., Ortiz, F., Sánchez-Chapado, M., Carballido, J., Castillón, I., Mateo, E., Romero, I., del Álamo, J. Fernández, Llanes, L., Blázquez, C., Sánchez-Encinas, M., Borrego, J., Téllez, M., Díez, L., Carrero, V. M., Pérez-Fernández, E., Fuentes-Ramirez, L., and Del Valle, S. García

Published
2020
Full Text
View/download PDF

3. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Author

Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., Ireland, R., Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., and Ireland, R.

Abstract

01 januari 2023, Item does not contain fulltext, This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

4. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group.

Author

Kern, W., Westers, Theresia M., Bellos, F., Bene, M.C., Bettelheim, P., Brodersen, L.E., Burbury, K., Chu, S.C., Cullen, M., Porta, M.D., Dunlop, A.S., Johansson, U., Matarraz, S., Oelschlaegel, U., Ogata, K., Porwit, A., Preijers, F.W., Psarra, K., Saft, L., Subirá, D., Weiß, E., Velden, V.H. van der, Loosdrecht, A. van de, Kern, W., Westers, Theresia M., Bellos, F., Bene, M.C., Bettelheim, P., Brodersen, L.E., Burbury, K., Chu, S.C., Cullen, M., Porta, M.D., Dunlop, A.S., Johansson, U., Matarraz, S., Oelschlaegel, U., Ogata, K., Porwit, A., Preijers, F.W., Psarra, K., Saft, L., Subirá, D., Weiß, E., Velden, V.H. van der, and Loosdrecht, A. van de

Abstract

01 januari 2023, Item does not contain fulltext, BACKGROUND: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML). METHODS: Thousand six hundred and eighty-two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized 'non-MDS' (i.e. no signs of MDS/CMML and limited signs of MDS/CMML) and 'in agreement with MDS' (i.e., in agreement with MDS/CMML). RESULTS: Flow cytometric readout categorized 60% of patients in agreement with MDS, 28% showed limited signs of MDS and 12% had no signs of MDS. In 81% of cases flow cytometric readouts and cytomorphologic diagnosis correlated. For high-risk MDS, the level of concordance was 92%. A total of 17 immunophenotypic aberrancies were found independently related to MDS/CMML in ≥1 of the subgroups of low-risk MDS, high-risk MDS, CMML. A cut-off of ≥3 of these aberrancies resulted in 80% agreement with cytomorphology (20% cases concordantly negative, 60% positive). Moreover, >3% myeloid progenitor cells were significantly associated with MDS (286/293 such cases, 98%). CONCLUSION: Data from this prospective multicenter study led to recognition of 17 immunophenotypic markers allowing to identify cases 'in agreement with MDS'. Moreover, data emphasizes the clinical utility of immunophenotyping in MDS diagnostics, given the high concordance between cytomorphology and the flow cytometric readout. Results from the current study challenge the application of the cytomorphologically defined cut-off of 5% blasts for flow cytometry and rather suggest a 3% cut-off for the latter.

Published
2023

5. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.

Author

Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., Loosdrecht, A. van de, Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., and Loosdrecht, A. van de

Abstract

01 januari 2023, Item does not contain fulltext, BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

7. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS

Author

Porwit, A, van de Loosdrecht, A A, Bettelheim, P, Brodersen, L Eidenschink, Burbury, K, Cremers, E, Della Porta, M G, Ireland, R, Johansson, U, Matarraz, S, Ogata, K, Orfao, A, Preijers, F, Psarra, K, Subirá, D, Valent, P, van der Velden, V H J, Wells, D, Westers, T M, Kern, W, and Béné, M C

Published
2014
Full Text
View/download PDF

9. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

Author

Westers, T M, Ireland, R, Kern, W, Alhan, C, Balleisen, J S, Bettelheim, P, Burbury, K, Cullen, M, Cutler, J A, Della Porta, M G, Dräger, A M, Feuillard, J, Font, P, Germing, U, Haase, D, Johansson, U, Kordasti, S, Loken, M R, Malcovati, L, te Marvelde, J G, Matarraz, S, Milne, T, Moshaver, B, Mufti, G J, Ogata, K, Orfao, A, Porwit, A, Psarra, K, Richards, S J, Subirá, D, Tindell, V, Vallespi, T, Valent, P, van der Velden, V H J, de Witte, T M, Wells, D A, Zettl, F, Béné, M C, and van de Loosdrecht, A A

Published
2012
Full Text
View/download PDF

21. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

Author

Westers, T.M. (Theresia), Cremers, E.M.P. (Eline), Oelschlaegel, U. (Uta), Johansson, U. (Ulrika), Bettelheim, P. (Peter), Matarraz, S. (S.), Orfao, A. (Alberto), Moshaver, B. (Bijan), Brodersen, L.E. (Lisa Eidenschink), Loken, M.R. (Michael), Wells, D.A. (Denise), Subirá, D. (Dolores), Cullen, C., Marvelde, J.G. (Jeroen) te, Velden, V.H.J. (Vincent) van der, Preijers, F.W.M.B. (Frank), Chu, S.-C. (Sung-Chao), Feuillard, J. (Jean), Guérin, E. (Estelle), Psarra, K. (Katherina), Porwit, A. (Anna), Saft, L. (Leonie), Ireland, R. (Robin), Milne, T. (Timothy), Béné, M.C., Witte, B.I. (Birgit), Della Porta, M.G. (Matteo), Kern, W. (Wolfgang), Loosdrecht, A.A. (Arjan) van de, Westers, T.M. (Theresia), Cremers, E.M.P. (Eline), Oelschlaegel, U. (Uta), Johansson, U. (Ulrika), Bettelheim, P. (Peter), Matarraz, S. (S.), Orfao, A. (Alberto), Moshaver, B. (Bijan), Brodersen, L.E. (Lisa Eidenschink), Loken, M.R. (Michael), Wells, D.A. (Denise), Subirá, D. (Dolores), Cullen, C., Marvelde, J.G. (Jeroen) te, Velden, V.H.J. (Vincent) van der, Preijers, F.W.M.B. (Frank), Chu, S.-C. (Sung-Chao), Feuillard, J. (Jean), Guérin, E. (Estelle), Psarra, K. (Katherina), Porwit, A. (Anna), Saft, L. (Leonie), Ireland, R. (Robin), Milne, T. (Timothy), Béné, M.C., Witte, B.I. (Birgit), Della Porta, M.G. (Matteo), Kern, W. (Wolfgang), and Loosdrecht, A.A. (Arjan) van de

Abstract

Current recommendations for diagnosing myelodysplastic syndromes endorse flow cytometry as an informative tool. Most flow cytometry protocols focus on the analysis of progenitor cells and the evaluation of the maturing myelomonocytic lineage. However, one of the most frequently observed features of myelodysplastic syndromes is anemia, which may be associated with dyserythropoiesis. Therefore, analysis of changes in flow cytometry features of nucleated erythroid cells may complement current flow cytometry tools. The multicenter study within the IMDSFlow Working Group, reported herein, focused on defining flow cytometry parameters that enable discrimination of dyserythropoiesis associated with myelodysplastic syndromes from non-clonal cytopenias. Data from a learning cohort were compared between myelodysplasia and controls, and results were validated in a separate cohort. The learning cohort comprised 245 myelodysplasia cases, 290 pathological, and 142 normal controls; the validation cohort comprised 129 myelodysplasia cases, 153 pathological, and 49 normal controls. Multivariate logistic regression analysis performed in the learning cohort revealed that analysis of expression of CD36 and CD71 (expressed as coefficient of variation), in combination with CD71 fluorescence intensity and the percentage of CD117+ erythroid progenitors provided the best discrimination between myelodysplastic syndromes and non-clonal cytopenias (specificity 90%; 95% confidence interval: 84–94%). The high specificity of this marker set was confirmed in the validation cohort (92%; 95% confidence interval: 86–97%). This erythroid flow cytometry marker combination may improve the evaluation of cytopenic cases with suspected myelodysplasia, particularly when combined with flow cytometry assessment of the myelomonocytic lineage.

Published
2017
Full Text
View/download PDF

22. Bicytopenia in the Elderly: Don’t Get Me Wrong!

Author

Gil, A., primary, Subirá, D., additional, Vázquez, A., additional, Arbeteta, J., additional, Eraña, I., additional, De Miguel, D., additional, Guillén, H., additional, Herrero, S., additional, Díaz, M., additional, Morales, M.D., additional, Golbano, N., additional, Pérez, A., additional, and Pinedo, B., additional

Published
2017
Full Text
View/download PDF

24. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS

Author

Porwit, A., Loosdrecht, A.A. van de, Bettelheim, P., Brodersen, L.E., Burbury, K., Cremers, E., Porta, M.G. Della, Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F.W., Psarra, K., Subirá, D., Valent, P., Velden, V.H. van der, Wells, D., Westers, T.M., Kern, W., Béné, M.C., Porwit, A., Loosdrecht, A.A. van de, Bettelheim, P., Brodersen, L.E., Burbury, K., Cremers, E., Porta, M.G. Della, Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F.W., Psarra, K., Subirá, D., Valent, P., Velden, V.H. van der, Wells, D., Westers, T.M., Kern, W., and Béné, M.C.

Abstract

Item does not contain fulltext

Published
2014

29. Standardization of flow cytometry in myelodysplastic syndromes: Report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

Author

Loosdrecht, A.A. (Arjan) van de, Alhan, C. (Canan), Béné, M.C., Della Porta, M.G. (Matteo), Dräger, A.M. (Angelika), Feuillard, J. (Jean), Font, P. (Patricia), Germing, U. (Ulrich), Haase, D. (Detlef), Homburg, C.H. (Christa), Ireland, R. (Robin), Jansen, J.H. (Joop), Kern, W. (Wolfgang), Malcovati, L. (Luca), Marvelde, J.G. (Jeroen) te, Mufti, G.J. (Ghulam), Ogata, K. (Kiyoyuki), Orfao, A. (Alberto), Ossenkoppele, G.J. (Gert), Porwit, A. (Anna), Preijers, F.W.M.B. (Frank), Richards, S.J. (Stephen), Schuurhuis, G.J. (Gerrit Jan), Subirá, D. (Dolores), Valent, P. (Peter), Velden, V.H.J. (Vincent) van der, Vyas, P. (Paresh), Westra, A.H. (August), Witte, T. de, Wells, D.A. (Denise), Loken, M.R. (Michael), Westers, T.M. (Theresia), Loosdrecht, A.A. (Arjan) van de, Alhan, C. (Canan), Béné, M.C., Della Porta, M.G. (Matteo), Dräger, A.M. (Angelika), Feuillard, J. (Jean), Font, P. (Patricia), Germing, U. (Ulrich), Haase, D. (Detlef), Homburg, C.H. (Christa), Ireland, R. (Robin), Jansen, J.H. (Joop), Kern, W. (Wolfgang), Malcovati, L. (Luca), Marvelde, J.G. (Jeroen) te, Mufti, G.J. (Ghulam), Ogata, K. (Kiyoyuki), Orfao, A. (Alberto), Ossenkoppele, G.J. (Gert), Porwit, A. (Anna), Preijers, F.W.M.B. (Frank), Richards, S.J. (Stephen), Schuurhuis, G.J. (Gerrit Jan), Subirá, D. (Dolores), Valent, P. (Peter), Velden, V.H.J. (Vincent) van der, Vyas, P. (Paresh), Westra, A.H. (August), Witte, T. de, Wells, D.A. (Denise), Loken, M.R. (Michael), and Westers, T.M. (Theresia)

Abstract

The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter flow cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Con

Published
2009
Full Text
View/download PDF

31. 137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group

Author

Westers, T.M., primary, Ireland, R., additional, Kern, W., additional, Alhan, C., additional, Balleisen, J.S., additional, Béné, M.C., additional, Bettelheim, P., additional, Burbury, K., additional, Cullen, M., additional, Cutler, J.A., additional, Porta, M.G. Della, additional, Drager, A.M., additional, Feuillard, J., additional, Font, P., additional, Germing, U., additional, Haase, D., additional, Johansson, U., additional, Kordasti, S., additional, Loken, M.R., additional, Malcovati, L., additional, te Marvelde, J.G., additional, Matarraz, S., additional, Milne, T., additional, Moshaver, B., additional, Mufti, G.J., additional, Ogata, K., additional, Orfao, A., additional, Porwit, A., additional, Psarra, K., additional, Richards, S.J., additional, Subirá, D., additional, Tindell, V., additional, Vallespi, T., additional, Valent, P., additional, van der Velden, V.H., additional, de Witte, T.M., additional, Wells, D.A., additional, Zettl, F., additional, and van de Loosdrecht, A.A., additional

Published
2011
Full Text
View/download PDF

47. High sensitivity flow cytometry immunophenotyping increases the diagnostic yield of malignant pleural effusions.

Author

Subirá D, Barriopedro F, Fernández J, Martínez R, Chara L, Castelao J, and García E

Subjects
Humans, Flow Cytometry methods, Immunophenotyping, Pleural Effusion, Malignant diagnosis
Abstract

Diagnosing malignant pleural effusions (MPE) is challenging when patients lack a history of cancer and cytopathology does not detect malignant cells in pleural effusions (PE). We investigated whether a systematic analysis of PE by flow cytometry immunophenotyping (FCI) had any impact on the diagnostic yield of MPE. Over 7 years, 570 samples from patients with clinical suspicion of MPE were submitted for the FCI study. To screen for epithelial malignancies, a 3-color FCI high sensitivity assay was used. The FCI results, qualified as "malignant" (FCI+) or "non-malignant" (FCI-), were compared to integrated definitive diagnosis established by clinicians based on all available information. MPE was finally diagnosed in 182 samples and FCI detected 141/182 (77.5%). Morphology further confirmed FCI findings by cytopathology detection of malignant cells in PE (n = 91) or histopathology (n = 29). Imaging tests and clinical history supported the diagnosis in the remaining samples. The median percentage of malignant cells was 6.5% for lymphoma and 0.23% for MPE secondary to epithelial cell malignancies. FCI identified a significantly lower percentage of EpCAM +  cells in cytopathology-negative MPE than in cytopathology-positive cases (0.02% vs. 1%; p < 0.0001). Interestingly, 29/52 MPE (55.8%) where FCI alerted of the presence of malignant cells were new diagnosis of cancer. Overall, FCI correctly diagnosed 456/522 samples (87.4%) suitable for comparison with cytopathology. These findings show that high sensitivity FCI significantly increases the diagnostic yield of MPE. Early detection of FCI + cases accelerates the diagnostic pathway of unsuspected MPE, thus supporting its implementation in clinical diagnostic work-up as a diagnostic tool., (© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)

Published
2023
Full Text
View/download PDF

48. The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes.

Author

Johansson U, McIver-Brown N, Cullen M, Duetz C, Dunlop A, Oelschlägel U, Psarra K, Subirá D, and Westers TM

Subjects
Humans, Flow Cytometry methods, Bone Marrow, Bone Marrow Cells, Myeloid Progenitor Cells, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes genetics
Abstract

Background: The bone marrow blast count is central to the diagnosis and monitoring of myelodysplastic syndromes (MDS). It is an independent risk factor for worse prognosis whether based on the morphology blast count or the flow cytometry (FC) myeloid progenitor (MyP) count. It is a principal population in FC MDS analysis also because once defined; it provides significant contributions to the overall FC MDS score., Methods: We elected to investigate inter-analyst agreement for the most fundamental parameter of the FC MDS diagnostic score: the MyP count. A common gating strategy was agreed and used by seven cytometrists for blind analysis of 34 routine bone marrows sent for MDS work-up. Additionally, we compared the results with a computational approach., Results: Concordance was excellent: Intraclass correlation was 0.993 whether measuring %MyP of total cells or CD45+ cells, and no significant difference was observed between files from different centers or for samples with abnormal MyP phenotypes. Computational and manual results were similar. Applying the common strategy to individual laboratories' control cohorts produced similar MyP reference ranges across centers., Conclusion: The FC MyP count offers a reliable diagnostic and prognostic measurement in MDS. The use of manual and computational approaches side by side may allow for optimizing both strategies. Considering its known prognostic power, the MyP count could be considered a useful and reliable addition to existing prognostic scoring systems., (© 2021 International Clinical Cytometry Society.)

Published
2023
Full Text
View/download PDF

49. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group.

Author

Kern W, Westers TM, Bellos F, Bene MC, Bettelheim P, Brodersen LE, Burbury K, Chu SC, Cullen M, Porta MD, Dunlop AS, Johansson U, Matarraz S, Oelschlaegel U, Ogata K, Porwit A, Preijers F, Psarra K, Saft L, Subirá D, Weiß E, van der Velden VHJ, and van de Loosdrecht A

Subjects
Humans, Flow Cytometry methods, Leukocytes, Immunophenotyping, Myelodysplastic Syndromes diagnosis, Leukemia, Myelomonocytic, Chronic diagnosis
Abstract

Background: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML)., Methods: Thousand six hundred and eighty-two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized 'non-MDS' (i.e. no signs of MDS/CMML and limited signs of MDS/CMML) and 'in agreement with MDS' (i.e., in agreement with MDS/CMML)., Results: Flow cytometric readout categorized 60% of patients in agreement with MDS, 28% showed limited signs of MDS and 12% had no signs of MDS. In 81% of cases flow cytometric readouts and cytomorphologic diagnosis correlated. For high-risk MDS, the level of concordance was 92%. A total of 17 immunophenotypic aberrancies were found independently related to MDS/CMML in ≥1 of the subgroups of low-risk MDS, high-risk MDS, CMML. A cut-off of ≥3 of these aberrancies resulted in 80% agreement with cytomorphology (20% cases concordantly negative, 60% positive). Moreover, >3% myeloid progenitor cells were significantly associated with MDS (286/293 such cases, 98%)., Conclusion: Data from this prospective multicenter study led to recognition of 17 immunophenotypic markers allowing to identify cases 'in agreement with MDS'. Moreover, data emphasizes the clinical utility of immunophenotyping in MDS diagnostics, given the high concordance between cytomorphology and the flow cytometric readout. Results from the current study challenge the application of the cytomorphologically defined cut-off of 5% blasts for flow cytometry and rather suggest a 3% cut-off for the latter., (© 2022 International Clinical Cytometry Society.)

Published
2023
Full Text
View/download PDF

50. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Author

van de Loosdrecht AA, Kern W, Porwit A, Valent P, Kordasti S, Cremers E, Alhan C, Duetz C, Dunlop A, Hobo W, Preijers F, Wagner-Ballon O, Chapuis N, Fontenay M, Bettelheim P, Eidenschink-Brodersen L, Font P, Johansson U, Loken MR, Te Marvelde JG, Matarraz S, Ogata K, Oelschlaegel U, Orfao A, Psarra K, Subirá D, Wells DA, Béné MC, Della Porta MG, Burbury K, Bellos F, van der Velden VHJ, Westers TM, Saft L, and Ireland R

Subjects
Humans, Flow Cytometry, Myelodysplastic Syndromes diagnosis
Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients., (© 2021 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results